A completed 90-day safety study conducted by Taipei Medical University provides important preclinical support for the continued development of C60-Ellagic acid and helps strengthen the scientific foundation behind C60 MD.
Key Highlights
A 90-day oral safety study has been completed
The study was conducted by Taipei Medical University
The research included both male and female rats
No test-article-related mortality was observed during the study period
No clear adverse effects on body weight were reported
In the major organs evaluated, no test-article-related toxic changes were identified
Under the conditions of this study, the reported no-observed-adverse-effect level (NOAEL) was at least 500 mg/kg body weight/day
A MEANINFUL MILESTONE
A More Credible Scientific Foundation
As interest in C60 continues to grow, so do expectations for credible research and transparent scientific evaluation.
At C60 MD, we believe meaningful progress comes not only from innovation itself, but also from rigorous validation, continued research, and respect for the scientific process. This latest study is a clear reflection of that commitment.
This 90-day safety study, conducted by Taipei Medical University, one of Taiwan’s leading academic and medical institutions, marks an important step forward in the continued development of C60-Ellagic acid.
Study Findings
According to the final report, the C60-Ellagic acid formulation demonstrated good tolerability under the conditions of the study.
No test-article-related mortality was observed during the study period, and no clear adverse effects on body weight were reported. In addition, no test-article-related toxic changes were identified in the major organs evaluated, including the liver, kidney, brain, and heart.
The report also stated that, in this animal model, the no-observed-adverse-effect level (NOAEL) was at least 500 mg/kg body weight/day.
Why This Study Matters
Safety evaluation is an essential part of any product’s long-term and responsible development.
This study not only adds meaningful preclinical safety data to support the continued development of C60 MD, but also further strengthens the scientific foundation behind it. Just as importantly, it reflects a research approach grounded in care, rigor, and accountability.
For C60 MD, this milestone represents more than the completion of a single report. It is an important step forward in building trust through science.
Further Reading
Readers interested in learning more about the study and its supporting data may refer to the full report for additional background on the research design and methodology.
Important Note: This article is based on a summary of findings from a preclinical animal toxicity study conducted in rats. It does not establish human efficacy and should not be interpreted as a medical claim.
Technological Background
The technology behind C60 MD products originates from the U.S. company SINAPU LLC CORPORATION, led by Simon Cao and Dr. Butzloff. Their unique technology derives from Richard Smalley, the father of carbon nanotubes, and combines quantum physics and nanotechnology to develop water-soluble C60 (fullerenol), greatly enhancing oral bioavailability (BA). This technology gives C60 nano-drug delivery capabilities, allowing it to penetrate the blood-brain barrier (BBB) and treat brain-related diseases such as Parkinson's, Alzheimer's, and dementia. These significant breakthroughs make water-soluble C60 highly promising for future preventive medicine and health applications.
